InvestSMART

Don't chew

They look like normal pills.
By · 25 Jun 2013
By ·
25 Jun 2013
comments Comments
They look like normal pills. But if your doctor writes a prescription for these pills in the not-too-distant future, you might hear a new twist on an old cliche: "Take two of these ingestible computers, and they will email me in the morning." Researchers and some start-ups are already preparing the next, even more intrusive, wave of computing: ingestible computers and minuscule sensors stuffed inside pills. bit.ly/174d5vc
Google News
Follow us on Google News
Go to Google News, then click "Follow" button to add us.
Share this article and show your support
Free Membership
Free Membership
InvestSMART
InvestSMART
Keep on reading more articles from InvestSMART. See more articles
Join the conversation
Join the conversation...
There are comments posted so far. Join the conversation, please login or Sign up.

Frequently Asked Questions about this Article…

Ingestible computers and sensors are minuscule electronic devices built into what look like normal pills. According to the article, these tiny sensors can be swallowed and are designed to send information — the piece even imagines them 'emailing' a doctor — making them a new class of internal health-monitoring technology.

The article suggests ingestible computers could be prescribed like pills and used to transmit health information directly to clinicians. They represent a next wave of computing that could change how doctors monitor patients by providing inside-the-body data that wasn’t easily available before.

The article notes that researchers and some start-ups are already preparing and developing ingestible computers and tiny sensors to be included inside pills, indicating a mix of academic and early-stage commercial activity in this area.

The term 'intrusive' in the article refers to the fact that these devices operate inside the human body and can actively send data to external parties. That inside-the-body data collection is a step beyond wearable or external devices, which is why the article frames it as more intrusive.

As described in the article, ingestible sensors could give doctors direct, timely information from inside a patient’s body — potentially improving monitoring, diagnosis or treatment decisions. For patients, that could mean more personalized care if the technology is adopted.

The article implies this is an emerging, early-stage area driven by researchers and start-ups, so investors should expect typical early-stage risks: technological and clinical validation, adoption by doctors and patients, privacy and data concerns, and an uncertain timeline to widespread use.

Because the article highlights research and start-up activity, simple ways to follow the space include watching academic research, health-tech news, start-up funding announcements, and clinical trial updates. These signals can show when the technology is moving from lab research toward real-world use.

The article suggests it could happen in the 'not-too-distant future' but doesn’t give a definitive timeline. While the technology is being prepared by researchers and start-ups, widespread medical prescribing will depend on validation, acceptance and implementation over time.